Perspective on Intradiscal Therapies for Lumbar Discogenic Pain: State of the Science, Knowledge Gaps, and Imperatives for Clinical Adoption
Morgan P Lorio,Jordan Lee Tate,Thomas J Myers,Jon E Block,Douglas P Beall
DOI: https://doi.org/10.2147/jpr.s441180
IF: 2.8319
2024-03-18
Journal of Pain Research
Abstract:Morgan P Lorio, 1 Jordan Lee Tate, 2 Thomas J Myers, 3 Jon E Block, 4 Douglas P Beall 5 1 Advanced Orthopedics, Altamonte Springs, FL, USA; 2 Southern Pain and Spine Associates, Jasper, GA, USA; 3 Paradigm Health System, Slidell, LA, USA; 4 Private Practice, San Francisco, CA, USA; 5 Comprehensive Specialty Care, Edmond, OK, USA Correspondence: Jon E Block, Private Practice, 2210 Jackson Street, Ste. 401, San Francisco, CA, 94115, USA, Tel +1(415) 775-7947, Email Specific clinical diagnostic criteria have established a consensus for defining patients with lumbar discogenic pain. However, if conservative medical management fails, these patients have few treatment options short of surgery involving discectomy often coupled with fusion or arthroplasty. There is a rapidly-emerging research effort to fill this treatment gap with intradiscal therapies that can be delivered minimally-invasively via fluoroscopically guided injection without altering the normal anatomy of the affected vertebral motion segment. Viable candidate products to date have included mesenchymal stromal cells, platelet-rich plasma, nucleus pulposus structural allograft, and other cell-based compositions. The objective of these products is to repair, supplement, and restore the damaged intervertebral disc as well as retard further degeneration. In doing so, the intervention is meant to eliminate the source of discogenic pain and avoid surgery. Methodologically rigorous studies are rare, however, and based on the best clinical evidence, the safety as well as the magnitude and duration of clinical efficacy remain difficult to estimate. Further, we summarize the US Food and Drug Administration's (FDA) guidance regarding the interpretation of the minimal manipulation and homologous use criteria, which is central to designating these products as a tissue or as a drug/device/biologic. We also provide perspectives on the core evidence and knowledge gaps associated with intradiscal therapies, propose imperatives for evaluating effectiveness of these treatments and highlight several new technologies on the horizon. Keywords: degenerative, disc, intradiscal, autologous, allogeneic, injection, regenerative, discogenic, pain Significant advancements in the pathoanatomical characterization of the degenerative processes of the intervertebral disc have been instrumental in establishing and refining clinical diagnostic criteria specific to patients with lumbar discogenic pain. 1–3 Although diagnosis can be difficult, salient features of physical examination have been defined to include axial midline low back pain, sitting intolerance, pain with flexion, positive provocation with sustained hip flexion, absence of motor/sensor/reflex change, and positive discography with or without non-radicular/non-sciatic referred leg pain in a sclerotomal distribution. 2,4 In a recently published quantitative evaluation of the global burden of disease, the Institute for Health Metrics and Evaluation (IHME) reported that out of 395 diseases, injuries, and impairments, low back pain was the leading cause of years lived with disability (YLD), responsible for approximately 64 million YLDs or 7.4% of total global YLDs in 2019. 1 Estimates suggest that as many as 40% of patients exhibiting persistently severe low back pain have diagnostic signs and symptoms of discogenic origin including imaging evidence of internal disc disruption and other findings associated with annular tearing. 5,6 If discogenic low back pain becomes chronic and refractory to conservative medical management, there are few therapeutic options short of surgical discectomy often coupled with total disc arthroplasty or instrumented interbody spine fusion. These options, such as utilizing cell-based and biomaterial engineering therapies to modify the physiology and possibly restore the structure of the degenerated intervertebral disc, may serve to fill the extensive treatment gap between conservative management and traditional spine surgery. Therapeutic candidates including mesenchymal stromal cells (MSCs), platelet-rich plasma (PRP), nucleus pulposus (NP) tissue, and related cell-based agents have been proposed and can be delivered minimally-invasively under fluoroscopic guidance via a needle-based approach. 7–15 Both autologous products and their allogeneic analogs have been studied for relief of discogenic pain. 14,15 The underlying mechanism of action can involve the differentiation of chondrogenic precursor cells into viable regenerated disc tissue as with the injection of MSCs or the direct implantation of native disc material as with allogeneic NP. Products have ranged from autologous bone marrow aspirate containing a cocktail of pluripotent -Abstract Truncated-
clinical neurology